Displaying drugs 626 - 650 of 8178 in total
Miglitol
Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body.
Miglitol should be taken at the start...
Approved
Matched Description: … amount of poly and oligosaccharides in the diet. ... used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of ... Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the …
LetibotulinumtoxinA
The aesthetic utility of botulinum toxin was discovered incidentally following its initial use in the treatment of facial spasmodic disorders in the early 1970s. The first aesthetic use of botulinum toxin was reported in 1989, when onabotulinumtoxinA (Botox) was used as a treatment for facial asymmetry resulting from iatrogenic facial...
Approved
Matched Description: … treatment of facial spasmodic disorders in the early 1970s. ... The aesthetic utility of botulinum toxin was discovered incidentally following its initial use in the ... [A249920] The first aesthetic use of botulinum toxin was reported in 1989, when [onabotulinumtoxinA] …
Methenamine
Methenamine is a heterocyclic organic compound with a cage-like structure similar to adamantane. In salt form it is used for the treatment of urinary tract infection (Example: methenamine hippurate which is the hippuric acid salt of methenamine).
Approved
Vet approved
Matched Description: … which is the hippuric acid salt of methenamine). ... In salt form it is used for the treatment of urinary tract infection (Example: methenamine hippurate …
Padimate O
Padimate O is an active sunscreen agent in cosmetics and over-the-counter sunscreen drug products in concentrations up to 8%, as regulated by the FDA . It is a structurally-related compound to DB02362 that absorbs UV-B rays to prevent photodamage. It penetrates human skin, and is shown to induce non-ligatable strand...
Approved
Kappadione
Kappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is not available in North America . It has been found to have carcinogenic potential in mammalian cells as...
Approved
Matched Description: … of mice [L1544]. ... Studies involving the active metabolite of this formulation, menadione, showed oocyte toxicity in a study …
Azelastine
Azelastine, a phthalazine derivative, is an antihistamine available as an intranasal spray for the treatment of allergic and vasomotor rhinitis and as an ophthalmic solution for the treatment of allergic conjunctivitis.[L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first...
Approved
Matched Description: … seasonal allergic rhinitis in patients 6 years of age and older. ... Azelastine, a phthalazine derivative, is an antihistamine available as an intranasal spray for the treatment of ... allergic and vasomotor rhinitis and as an ophthalmic solution for the treatment of allergic conjunctivitis …
Dalfampridine
Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Approved
Abaloparatide
Abaloparatide is an N-terminal analog of parathyroid hormone-related protein (PTHrP) and an agonist at the parathyroid hormone type 1 (PTH1) receptor. It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and human PTHrP 1-34. Abaloparatide and PTHrP share the first 21 amino acids...
Approved
Investigational
Matched Description: … Abaloparatide is an N-terminal analog of parathyroid hormone-related protein (PTHrP) [A256778] and an ... [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis …
Bulevirtide
Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality.[A226340,L30235] Until recently, there have been extremely limited treatments available for Hepatitis D infection. Bulevirtide, also known as Hepcludex, is a...
Approved
Investigational
Matched Description: … of cirrhosis, severe decompensation of liver function, and an increased risk of mortality. ... Completion of this clinical trial is anticipated in early 2023.[L30240] ... chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead. …
Meprobamate
A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated)....
Approved
Illicit
Matched Description: … It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia ... with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of …
Cresol
Cresol is a hydroxytoluene that can be extracted naturally from coal tar or made synthetically. Pure cresol is a mixture of ortho-, meta-, and para- isomers. Cresols are precursors or synthetic intermediates to various other compounds and materials, including plastics, pesticides, pharmaceuticals, disinfectants, and dyes. Ingestion of cresol induces toxicity...
Approved
Matched Description: … Ingestion of cresol induces toxicity in humans and can lead to burning of the mouth and throat, abdominal ... Pure cresol is a mixture of ortho-, meta-, and para- isomers. …
Ceftazidime
Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis,...
Approved
Matched Description: … a family of enzymes known as "penicillin-binding proteins" (PBPs). ... A232920] β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of ... glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of …
Aluminum hydroxide
Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects.
Approved
Investigational
Matched Description: … Subsequent increases in pH may inhibit the action of pepsin. …
Potassium
Potassium is an essential nutrient, like Calcium and Magnesium. It was identified as a shortfall nutrient by the 2015-2020 Advisory Committee of Dietary Guidelines for Americans. Many conditions and diseases interfere with normal body potassium balance, and underconsumption of potassium is one example. Hypokalemia (low potassium) or hyperkalemia (high potassium)...
Approved
Experimental
Matched Description: … It was identified as a shortfall nutrient by the 2015-2020 Advisory Committee of Dietary Guidelines for ... A186928] Many conditions and diseases interfere with normal body potassium balance, and underconsumption of ... Examples of potassium formulations include potassium citrate, potassium chloride, and potassium with …
Lesinurad
Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with...
Approved
Investigational
Matched Description: … Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia ... Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of ... It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake …
Corticorelin ovine triflutate
Corticorelin, available commercially as corticorelin ovine triflutate (tradename Acthrel), is a synthetic form of the peptide human corticotropin-releasing hormone (hCRH), a potent stimulator of adrenocorticotropic hormone (ACTH) release from the anterior pituitary. Endogenous forms hCRH are involved in the stress response and its main function is stimulation of the pituitary...
Approved
Matched Description: … of a pituitary source from an ectopic source of excessive ACTH secretion. ... It provides a differential diagnosis for Cushing's disease (a pituitary source of ACTH excess) or of ... ectopic ACTH syndrome (an ectopic source of ACTH excess). …
Lenograstim
Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.
Approved
Investigational
Durlobactam
Durlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. It is typically given in combination with sulbactam to protect it from degradation by certain serine-beta-lactamases. The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023. It is used to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial...
Approved
Investigational
Matched Description: … [L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023 ... pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of …
Lumiracoxib
Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling...
Approved
Investigational
Matched Description: … On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the ... FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver …
Enprofylline
Enprofylline is a derivative of theophylline which shares bronchodilator properties. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. Long-term enprofylline administration may be associated with elevation in liver enzyme levels and unpredictable blood levels.
Approved
Experimental
Matched Description: … Enprofylline is a derivative of theophylline which shares bronchodilator properties. ... Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular …
Tenoxicam
Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.
Approved
Setmelanotide
Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. It is an agonist of the melanocortin 4 receptor. Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. Other...
Approved
Investigational
Matched Description: … [L24474] It is an agonist of the melanocortin 4 receptor. ... [A224449] Patients taking setmelanotide experienced an average weight loss of 0.6 kg/week. …
Eculizumab
Eculizumab is a monoclonal antibody that targets complement protein C5.[L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.[L6919,A2245,A2246]
Eculizumab was granted FDA approval on 16 March 2007. In Q1 2023, the EMA's Committee for Medicinal Products...
Approved
Investigational
Matched Description: … two formulations of eculizumab indicated for the treatment of paroxysmal nocturnal hemoglobinuria. ... is used to treat a number of autoimmune conditions. ... [L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which …
Ubrogepant
Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor...
Approved
Investigational
Matched Description: … advance in migraine headache treatment and may become the new standard of therapy in the treatment of ... Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. ... first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of …
Labetalol
Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730]
Labetalol was granted FDA approval on 1 August 1984.
Approved
Matched Description: … 25% of the mixture. ... Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up …
Displaying drugs 626 - 650 of 8178 in total